Amit Subedi
Education and Training
B.Pharmacy | Maharajgunj Medical Campus | Kathmandu, Nepal
M.S. Pharmacy | Yeungnam University | Daegu, South Korea
Ph.D. Pharmacology | Saitama University | Saitama, Japan
Postdoctoral Fellow | University Health Network | Toronto, Canada
Teaching Interests
Dr. Subedi’s teaching interests include various topics in pharmacology including oncology, cardiovascular and infectious diseases.
Scholarly Interests
Dr. Amit Subedi’s research centers on the discovery of small molecules and peptides targeting multiple disease indications. One major area of his work focuses on immune evasion—a hallmark of cancer. Recent reports indicate that TROP2 mediates immune exclusion, and that blocking TROP2 in combination with anti-PD-1 therapy can restore tumor inhibition. Accordingly, his laboratory aims to develop anti-TROP2 molecules that prevent cancer cells from escaping immune surveillance.
Dr. Subedi also investigates chronic inflammatory and obesity-related conditions. Mutations such as TET2 and TCL1A are implicated in chronic inflammation, and their inhibition has been shown to suppress pathogenic mutant clones. In addition, inhibition of incretin receptors such as GLP-1R and GIPR induces body-weight loss. Dr. Subedi’s longstanding research effort is directed toward discovering and developing small molecules capable of targeting these mechanisms to combat chronic inflammation and obesity.
Selected Recent Publications
- Yang, Y., Cathelin, S., Liu, A. C. H., Subedi, A., Maher, A., Hosseini, M., Ayyathan, D. M., Vanner, R., & Chan, S. M. (2025). TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling. Nature Communications, 16(1), 2384.
- Cathelin, S., Sharon, D., Subedi, A., Cojocari, D., Phillips, D. C., Leverson, J. D., MacBeth, K. J., Nicolay, B., Narayanaswamy, R., & Ronseaux, S. (2022). Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia, 36(3), 869–872.
- Subedi, A., Liu, Q., Ayyathan, D. M., Sharon, D., Cathelin, S., Hosseini, M., Xu, C., Voisin, V., Bader, G. D., & D’Alessandro, A. (2021). Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell, 28(10), 1851–1867.e8.
- Subedi, A., Muroi, M., Futamura, Y., Kawamura, T., Aono, H., Nishi, M., Ryo, A., Watanabe, N., & Osada, H. (2019). A novel inhibitor of tumorspheres reveals the activation of the serine biosynthetic pathway upon mitochondrial inhibition. FEBS Letters, 593(8), 763–776.
- Subedi, A., Futamura, Y., Nishi, M., Ryo, A., Watanabe, N., & Osada, H. (2016). High-throughput screening identifies artesunate as a selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism. Biochemical and Biophysical Research Communications, 477(4), 737–742.
- Subedi, A., Shimizu, T., Ryo, A., Sanada, E., Watanabe, N., & Osada, H. (2016). Discovery of novel selenium derivatives as Pin1 inhibitors by high-throughput screening. Biochemical and Biophysical Research Communications, 474(3), 528–533.
- Tilija Pun, N., Subedi, A*., Kim, M. J., & Park, P.-H. (2015). Globular adiponectin causes tolerance to LPS-induced TNF-α expression via autophagy induction in RAW 264.7 macrophages: Involvement of SIRT1/FoxO3A axis. PLoS ONE, 10(5), e0124636.
- Subedi, A., & Park, P.-H. (2013). Autocrine and paracrine modulation of microRNA-155 expression by globular adiponectin in RAW 264.7 macrophages: Involvement of MAPK/NF-κB pathway. Cytokine, 64(3), 638–641.
- Subedi, A., Kim, M. J., Nepal, S., Lee, E.-S., Kim, J.-A., Sohn, D.-H., Song, K., Lee, S. H., Park, W. S., & Jeong, B.-S. (2013). Globular adiponectin modulates expression of programmed cell death 4 and miR-21 in RAW 264.7 macrophages through the MAPK/NF-κB pathway. FEBS Letters, 587(10), 1556–1561.
- Nepal, S., Kim, M. J., Subedi, A., Lee, E.-S., Yong, C. S., Kim, J.-A., Kang, W., Kwak, M.-K., Arya, D. S., & Park, P.-H. (2012). Globular adiponectin inhibits ethanol-induced apoptosis in HepG2 cells through heme oxygenase-1 induction. Biochemical Pharmacology, 84(7), 974–983.
Selected Recent Presentations
- Subedi, A., Zahreddine, H. A., Cousineau, S. E., Wargachuk, R., Wang, X., Lai, L., Hou, D., Undzys, E., Ngan, G., & da Cruz, L. (2025). KJ-103: First-in-class naked anti-TROP2 HCAb with immune modulatory mechanisms and tumor regression potential in clinical trials. American Association of Cancer Research, 2024, Chicago, USA.
- Cousineau, S. E., Subedi, A., Wargachuk, R., The, J., Wang, X., Hou, W., Nair, A., Qiu, W., Zhou, A., & Cheng, T. (2024). The AI-powered KisoSeek™ platform identifies functional anti-TROP2 heavy-chain antibodies with potent anti-cancer activity. American Association of Cancer Research, 2023, San Diego, USA.
- Yao, S., Zahreddine, H., Subedi, A., Gong, L., Nair, A., Zhou, A., Cheng, T., Undzys, E., Hou, D., & Lai, L. (2023). Functional characterization of KJ-103, a novel therapeutic anti-TROP2 heavy chain-only antibody. American Association of Cancer Research, Orlando, 2022, USA.
- Subedi, A., Liu, Q., Sharon, D., Xu, C., Voisin, V., Bader, G. D., Wang, J., & Chan, S. M. (2018). Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity selectively targets human acute myeloid leukemia stem cells. American Society of Hematology, 2018, San Diego, USA.
Awards and Honors
- Winner, Biotech Venture Pitch Competition, $10,000 CAD, 2022, Toronto, Canada
- New Idea Award, Leukemia & Lymphoma Society, $75,000 USD, 2018
- Best Poster Award, American Society of Hematology, 2018, San Diego
- Best Poster Award, Targeting Cancer Stem Cells, RIKEN Summer School, 2014, Japan
- International Program Associate/PhD Fellowship, RIKEN Scholar, 2013–2016, Japan
- Gold Medal – Bachelor of Pharmacy Excellence Award, 2010, Nepal
- Merit Award – Fully Funded Government Scholarship, Bachelor of Pharmacy, 2006–2010, Nepal
